23 May 2024
An exciting milestone in our pursuit to make CAR T-cell therapy a standard of care in New Zealand, the Environmental Protection Authority NZ has approved use of chimeric antigen receptor (CAR) T-cells in our phase 2 clinical trial with BioOra.
As a trial of this kind had never been done before in New Zealand, our team has put significant time and effort into working with national regulatory bodies such as the EPA and MedSafe to navigate and establish the necessary regulatory pathways to bring CAR T-cell technology to New Zealand.
In doing so, we have opened doors for similar life-saving cell therapy trials to be undertaken here in the future - whether our own or others.
Related articles
Developing next generation CAR T-cell therapies for more equitable cancer care
30 October 2025
Read more
Faster CARs: overcoming cellular exhaustion to enhance cancer immunotherapies
29 October 2025
Read more
Malaghan CAR T programme wins KiwiNet Research Commercialisation Award
23 October 2025
Read more
Study explores wearable devices to improve blood cancer patient monitoring
8 October 2025
Read more
Blood, sweat and cells: The making of New Zealand’s first CAR T-cell trial
24 September 2025
Read more
Malaghan cancer research double finalists in KiwiNet Research Commercialisation awards
7 August 2025
Read more